Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: A novel epigenetic-targeting approach in acute myeloid leukemia

Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously we demonstrated that AML patients with higher miR-29b expression had better response to the hypomethylating agent decitabine. Ther...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mims, Alice, Walker, Alison R., Huang, Xiaomeng, Sun, Jin, Wang, Hongyan, Santhanam, Ramasamy, Dorrance, Adrienne M., Walker, Chris, Hoellerbauer, Pia, Tarighat, Somayeh S., Chan, Kenneth K., Klisovic, Rebecca B., Perrotti, Danilo, Caligiuri, Michael A., Byrd, John C., Chen, Ching-Shih, Lee, L. James, Jacob, Samson, Mrózek, Krzysztof, Bloomfield, Clara D., Blum, William, Garzon, Ramiro, Schwind, Sebastian, Marcucci, Guido
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3764604/
https://ncbi.nlm.nih.gov/pubmed/23178755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.342
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items